Gage Brittany, Lamb Julia, Dahri Karen
is a student in the Entry-to-Practice Doctor of Pharmacy program (Class of 2021), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
, BSc, BScPharm, PharmD, ACPR, FCSHP, is a Pharmacotherapeutic and Research Specialist (Internal Medicine) with Vancouver General Hospital and an Assistant Professor (Partner) with the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
Can J Hosp Pharm. 2021 Spring;74(2):110-116. Epub 2021 Apr 1.
In the past decade, the number of inhaled devices approved for management of chronic obstructive pulmonary disease (COPD) has tripled. Management of at-home inhaled COPD therapy can present a problem when patients are admitted to hospital, because only a limited number of these therapies are currently included in hospital formularies and there is a lack of established interchanges.
To characterize and evaluate the appropriateness of management of patients' before-admission inhaled therapy upon hospital admission.
This retrospective chart review involved patients with COPD admitted to a tertiary care centre over a 1-year period (October 2017 to September 2018). Before-admission inhaled therapy was compared with inhalers ordered in hospital and at discharge. Inhaler device type, regimen, therapeutic class, and disease severity were used to assess the appropriateness of inpatient management.
The charts of 200 patients were reviewed. Of these patients, 124 (62%) were kept on the same inhaler, 43 (22%) had one or more of their inhalers discontinued, 35 (18%) had to provide their own medication, and 24 (12%) had their medication changed to a formulary equivalent. An average delay of 2.6 (standard deviation 3.2) days occurred when patients provided their own medication. Formulary substitution resulted in most patients receiving a medication from the same class (75% [18/24]); however, other aspects of therapy, such as device type (17% [4/24]), regimen (29% [7/24]) and drug combination (47% [9/19]), were not maintained. Only 55% (6/11) received an equivalent dose of inhaled corticosteroids when the medication was interchanged to a formulary inhaler.
The majority of patients' inhaled therapies continued unchanged upon admission to hospital, which suggests that despite the proliferation of new inhalers on the market, their use is still limited. For patients who did require interchange to formulary inhalers, maintenance of the same regimen, device, and combination product was rare. Provision of the medication supply by patients themselves often resulted in a delay in therapy.
在过去十年中,获批用于慢性阻塞性肺疾病(COPD)管理的吸入装置数量增加了两倍。当患者住院时,家庭吸入性COPD治疗的管理可能会出现问题,因为目前医院处方中仅包含有限数量的此类疗法,并且缺乏既定的互换方案。
描述和评估患者入院前吸入治疗在住院时管理的适宜性。
这项回顾性病历审查涉及在1年期间(2017年10月至2018年9月)入住三级护理中心的COPD患者。将入院前吸入治疗与住院期间和出院时所开的吸入器进行比较。使用吸入器装置类型、治疗方案、治疗类别和疾病严重程度来评估住院管理的适宜性。
审查了200例患者的病历。在这些患者中,124例(62%)继续使用相同的吸入器,43例(22%)停用了一种或多种吸入器,35例(18%)不得不自行提供药物,24例(12%)的药物被换成了处方等效药物。患者自行提供药物时平均延迟2.6天(标准差3.2天)。处方替换导致大多数患者接受同一类别的药物(75%[18/24]);然而,治疗的其他方面,如装置类型(17%[4/24])、治疗方案(29%[7/24])和药物组合(47%[9/19])未得到维持。当药物换成处方吸入器时,只有55%(6/11)的患者接受了等效剂量的吸入性糖皮质激素。
大多数患者入院后吸入治疗保持不变,这表明尽管市场上新型吸入器不断增加,但其使用仍然有限。对于确实需要换成处方吸入器的患者,维持相同的治疗方案、装置和组合产品的情况很少见。患者自行提供药物供应通常会导致治疗延迟。